• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TIPS 可改善 HCC 合并症状性门脉高压患者的预后:多中心经验。

TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.

机构信息

Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, 510630, China.

Department of Minimally Invasive & Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.

出版信息

Cancer Imaging. 2022 Feb 19;22(1):13. doi: 10.1186/s40644-022-00451-9.

DOI:10.1186/s40644-022-00451-9
PMID:35183265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8858571/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) with symptomatic portal hypertension (SPH) has poor prognosis. A transjugular intrahepatic portosystemic shunt (TIPS) relieves SPH, but its application in HCC remains unclear. We evaluated TIPS efficacy in patients with HCC and SPH.

METHODS

Pre- and post-TIPS Child-pugh(C-P) scores and stages in 123 HCC patients with SPH from three centers were compared. The impact of postoperative C-P stage indicators on overall survival (OS) was explored.

RESULTS

Post-TIPS responses to SPH included complete response (CR) (92 [74.8%]), partial response (PR) (23 [18.7%]), and nonresponse (NR) (8 [6.5%]). The control (proportion of CR and PR) for SPH was 93.5%. Median C-P scores pre-TIPS and at one month post-TIPS were 8 (IQR 6-9) and 7 (IQR 6-8), respectively (P < 0.001). Forty-one (33.3%) patients had C-P downstaging; 73 (59.3%) had lowered C-P scores; and 73 (59.3%) received intrahepatic local therapy post-TIPS. The median OS was 10.7 (1.1-55.2) months. Among the five indicators of C-P stage, lower post-TIPS ascites grading [(0/1)/(2/3); P = 0.014, HR = 0.31 (95% CI: 0.12-0.79)] and bilirubin [< 34/ ≥ 34 µmol/L; P = 0.022, HR = 0.47 (95% CI: 0.23-0.82)] and prothrombin time prolongation < 6 s [< 6/ ≥ 6 s; P = 0.001, HR = 0.17 (95% CI: 0.06-0.47)] were independent protective indicators of OS. These three indicators were included in the nomogram model to predict survival probabilities.

CONCLUSIONS

TIPS is safe and effective for HCC with SPH. This procedure can relieve the symptoms, enable subsequent antitumor therapy, and bring survival benefits, possibly through improved liver function by reducing C-P stage.

摘要

背景

伴有症状性门静脉高压症(SPH)的肝细胞癌(HCC)预后较差。经颈静脉肝内门体分流术(TIPS)可缓解 SPH,但在 HCC 中的应用尚不清楚。我们评估了 TIPS 在 HCC 伴 SPH 患者中的疗效。

方法

比较了来自三个中心的 123 例 HCC 伴 SPH 患者 TIPS 前后的 Child-pugh(C-P)评分和分期。探讨了术后 C-P 分期指标对总生存期(OS)的影响。

结果

SPH 的 TIPS 后反应包括完全缓解(CR)(92[74.8%])、部分缓解(PR)(23[18.7%])和无反应(NR)(8[6.5%])。SPH 的对照(CR 和 PR 的比例)为 93.5%。TIPS 前和 TIPS 后一个月的中位 C-P 评分分别为 8(IQR 6-9)和 7(IQR 6-8)(P<0.001)。41(33.3%)例患者 C-P 降级;73(59.3%)例患者 C-P 评分降低;73(59.3%)例患者在 TIPS 后接受了肝内局部治疗。中位 OS 为 10.7(1.1-55.2)个月。在 C-P 分期的五个指标中,较低的 TIPS 后腹水分级[(0/1)/(2/3);P=0.014,HR=0.31(95%CI:0.12-0.79)]和胆红素[<34/≥34µmol/L;P=0.022,HR=0.47(95%CI:0.23-0.82)]和凝血酶原时间延长[<6/≥6s;P=0.001,HR=0.17(95%CI:0.06-0.47)]是 OS 的独立保护指标。这三个指标被纳入预测生存概率的列线图模型中。

结论

TIPS 治疗 HCC 伴 SPH 安全有效。该方法可缓解症状,为后续抗肿瘤治疗提供便利,并带来生存获益,可能通过降低 C-P 分期改善肝功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/8858571/90717564890a/40644_2022_451_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/8858571/df41937f836d/40644_2022_451_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/8858571/054bc826b3df/40644_2022_451_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/8858571/90717564890a/40644_2022_451_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/8858571/df41937f836d/40644_2022_451_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/8858571/054bc826b3df/40644_2022_451_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/8858571/90717564890a/40644_2022_451_Fig3_HTML.jpg

相似文献

1
TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.TIPS 可改善 HCC 合并症状性门脉高压患者的预后:多中心经验。
Cancer Imaging. 2022 Feb 19;22(1):13. doi: 10.1186/s40644-022-00451-9.
2
TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension.TIPS 联合序贯系统治疗伴肿瘤栓子相关症状性门静脉高压的晚期 HCC 患者。
Eur Radiol. 2022 Oct;32(10):6777-6787. doi: 10.1007/s00330-022-08705-7. Epub 2022 Apr 20.
3
Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.经颈静脉肝内门体分流术联合其他干预措施治疗门静脉高压性肝细胞癌
World J Gastroenterol. 2015 Nov 21;21(43):12439-47. doi: 10.3748/wjg.v21.i43.12439.
4
Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.经颈静脉肝内门体分流术治疗门静脉高压后门静脉高压症患者肝细胞癌的危险因素及生存分析。
J Cancer Res Ther. 2018;14(4):826-832. doi: 10.4103/jcrt.JCRT_930_17.
5
Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.肝细胞癌合并门静脉高压患者经颈静脉肝内门体分流术后肝性脑病的危险因素
J Gastrointestin Liver Dis. 2015 Sep;24(3):301-7. doi: 10.15403/jgld.2014.1121.243.yao.
6
Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.经颈静脉肝内门体分流术治疗合并门静脉癌栓的肝细胞癌门静脉高压症
Cardiovasc Intervent Radiol. 2017 Sep;40(9):1372-1382. doi: 10.1007/s00270-017-1655-8. Epub 2017 May 9.
7
The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma.经颈静脉肝内门体分流术(TIPS)在治疗肝细胞癌合并门静脉高压症患者中的作用。
Medicina (Kaunas). 2023 Jun 15;59(6):1150. doi: 10.3390/medicina59061150.
8
Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombus-Related Symptomatic Portal Hypertension.经颈静脉肝内门体分流术治疗伴有门静脉主干肿瘤血栓相关症状性门静脉高压的晚期肝细胞癌
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101305. doi: 10.1016/j.jceh.2023.101305. Epub 2023 Nov 18.
9
Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma.经颈静脉肝内门体分流术(TIPSS)治疗40例肝细胞癌患者的疗效与安全性
Aliment Pharmacol Ther. 2015 Jan;41(1):126-36. doi: 10.1111/apt.12994. Epub 2014 Oct 20.
10
Percutaneous transhepatic balloon-assisted transjugular intrahepatic portosystemic shunt for chronic, totally occluded, portal vein thrombosis with symptomatic portal hypertension: procedure technique, safety, and clinical applications.经皮经肝球囊辅助经颈静脉肝内门体分流术治疗慢性、完全闭塞性门静脉血栓形成伴症状性门静脉高压:操作技术、安全性和临床应用。
Eur Radiol. 2015 Dec;25(12):3431-7. doi: 10.1007/s00330-015-3777-1. Epub 2015 Apr 23.

引用本文的文献

1
Clinical significance of transjugular intrahepatic portosystemic shunting for hepatocellular carcinoma complicated with portal hypertension.经颈静脉肝内门体分流术治疗肝细胞癌合并门静脉高压症的临床意义
J Gastrointest Oncol. 2025 Aug 30;16(4):1648-1657. doi: 10.21037/jgo-2025-365. Epub 2025 Aug 27.
2
Outcomes of transjugular intrahepatic portosystemic shunt creation for the management of portal hypertension complications in cancer patients.经颈静脉肝内门体分流术治疗癌症患者门静脉高压并发症的疗效
Abdom Radiol (NY). 2025 May 28. doi: 10.1007/s00261-025-05013-8.
3
Efficacy and safety of TACE combined with TKIs and PD-1 inhibitors in HCC patients with prior TIPS.

本文引用的文献

1
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.乐伐替尼治疗肝细胞癌:从临床前机制到抗癌治疗。
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188391. doi: 10.1016/j.bbcan.2020.188391. Epub 2020 Jul 10.
2
Autoantibody signature in hepatocellular carcinoma using seromics.基于血清蛋白质组学的肝细胞癌自身抗体特征
J Hematol Oncol. 2020 Jul 2;13(1):85. doi: 10.1186/s13045-020-00918-x.
3
Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study.
经颈静脉肝内门体分流术(TIPS)治疗后肝细胞癌(HCC)患者中,肝动脉化疗栓塞术(TACE)联合酪氨酸激酶抑制剂(TKIs)及程序性死亡受体1(PD-1)抑制剂的疗效与安全性
Front Oncol. 2025 Apr 24;15:1570029. doi: 10.3389/fonc.2025.1570029. eCollection 2025.
4
Fully Covered Stent-TIPS for Advanced HCC Patients with Portal Vein Tumor Thrombus-Related Severe Symptomatic Portal Hypertension.全覆膜支架-经颈静脉肝内门体分流术治疗伴有门静脉癌栓相关严重症状性门静脉高压的晚期肝癌患者
J Hepatocell Carcinoma. 2025 Jan 14;12:29-41. doi: 10.2147/JHC.S491153. eCollection 2025.
5
Efficacy and safety of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma-A systematic review and meta-analysis.经颈静脉肝内门体分流术治疗肝细胞癌的疗效和安全性:系统评价和荟萃分析。
Indian J Gastroenterol. 2024 Dec;43(6):1121-1135. doi: 10.1007/s12664-024-01646-7. Epub 2024 Aug 10.
6
Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma.经颈静脉肝内门体分流术与肝细胞癌肝移植候选者更好的等待名单管理相关。
Transpl Int. 2024 Jun 26;37:12781. doi: 10.3389/ti.2024.12781. eCollection 2024.
7
Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombus-Related Symptomatic Portal Hypertension.经颈静脉肝内门体分流术治疗伴有门静脉主干肿瘤血栓相关症状性门静脉高压的晚期肝细胞癌
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101305. doi: 10.1016/j.jceh.2023.101305. Epub 2023 Nov 18.
8
Emergent TIPS for acute gastroesophageal variceal bleeding in cirrhotic patients with hepatocellular carcinoma.急性胃食管静脉曲张出血的紧急处理:伴肝细胞癌的肝硬化患者
Abdom Radiol (NY). 2024 Mar;49(3):900-907. doi: 10.1007/s00261-023-04088-5. Epub 2023 Nov 27.
9
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.经颈静脉肝内门体分流术(TIPS)在 HCC 及其他肝脏恶性肿瘤中的风险和获益:文献综述。
BMC Gastroenterol. 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0.
10
Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review.经颈静脉肝内门体分流术治疗肝细胞癌患者:系统评价。
United European Gastroenterol J. 2023 Oct;11(8):733-744. doi: 10.1002/ueg2.12454. Epub 2023 Sep 22.
肝癌合并门静脉癌栓患者肝切除术后的真实长期生存:一项全国性研究。
Hepatol Int. 2020 Sep;14(5):754-764. doi: 10.1007/s12072-020-10032-2. Epub 2020 Apr 6.
4
Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion.用于识别伴有肝静脉侵犯的肝细胞癌患者肝切除术候选者的预测模型。
Br J Surg. 2020 Jun;107(7):865-877. doi: 10.1002/bjs.11524. Epub 2020 Apr 4.
5
Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma.列线图预测肝癌患者肝切除术后肝功能不全风险和长期生存的建立与验证。
Ann Surg. 2021 Dec 1;274(6):e1209-e1217. doi: 10.1097/SLA.0000000000003803.
6
Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan.中期肝癌患者预后的预测:日本全国数据库中肿瘤标志物评分的验证
Liver Cancer. 2019 Oct;8(5):403-411. doi: 10.1159/000495944. Epub 2019 Feb 18.
7
Systemic Treatment for Advanced Hepatocellular Carcinoma.晚期肝细胞癌的全身治疗
Liver Cancer. 2019 Oct;8(5):341-358. doi: 10.1159/000496439. Epub 2019 Mar 6.
8
Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma.经颈静脉肝内门体分流术联合姑息治疗在肝细胞癌患者中的安全性和有效性
World J Clin Cases. 2019 Jul 6;7(13):1599-1610. doi: 10.12998/wjcc.v7.i13.1599.
9
Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.早期 TIPS(经颈静脉肝内门体分流术)联合覆膜支架与标准治疗对肝硬化急性静脉曲张出血患者的随机对照试验。
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):587-598. doi: 10.1016/S2468-1253(19)30090-1. Epub 2019 May 29.
10
Smaller-Diameter Covered Transjugular Intrahepatic Portosystemic Shunt Stents Are Associated With Increased Survival.较小直径的覆膜经颈静脉肝内门体分流术支架与生存率提高相关。
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2793-2799.e1. doi: 10.1016/j.cgh.2019.03.042. Epub 2019 Mar 30.